This suggests that the relationship between tau deposition and neuronal loss will only be observed in a pathological context, and highlights the importance of discriminating between CN subjects who are likely to be at a preclinical stage of AD, and those who are not. This evidence concerns the gene MAPT and Alzheimer disease.